# Extracellular Vesicles From Mesenchymal Stromal Cells Drive Muscle and Neuronal Regeneration Through TNFα Modulation

**Authors:** Agner Henrique Dorigo Hochuli, Stefania D'Agostino, Lucia Rossi, Beatrice Auletta, Leonardo Nogara, Giovanni Tafuro, Giuseppe Germano, Alice Zaramella, Paola Bisaccia, Francesca Cecchinato, Carlo Biz, Gabrielis Kundrotas, Pietro Ruggieri, Alessandra Semenzato, Maurizio Muraca, Filippo Romanato, Piergiorgio Gamba, Marcin Jurga, Bert Blaauw, Anna Urciuolo, Michela Pozzobon

PMC · DOI: 10.1002/jev2.70237 · 2026-03-11

## TL;DR

This study shows that extracellular vesicles from mesenchymal stromal cells help regenerate muscle and nerve tissue by reducing inflammation through TNFα modulation.

## Contribution

The study identifies TNFα modulation as a key mechanism by which extracellular vesicles promote muscle and neuronal regeneration.

## Key findings

- EVs protect muscle cells from death and stimulate proliferation by downregulating TNFα.
- EVs reduce neuroinflammation and promote axon sprouting in spinal cord models by inhibiting TNFα.
- GMP-grade EVs show potential for clinical applications in tissue regeneration.

## Abstract

Muscle defects caused by accidents, tumour resection and congenital malformations affect paediatric and adult patients. In this context, the neural‐muscle regeneration potential of mesenchymal stromal/stem cells derived from extracellular vesicles (EV) has been demonstrated by our group and others, but the mechanism by which EVs act remains unknown. This work aimed to investigate the neural‐muscle regeneration mechanism shown by EVs in vivo using three‐dimensional (3D) multicellular in vitro models. We used (1) human muscle decellularised tissue (ECM) engineered with human muscle precursor cells (hMPC) together with macrophages THP‐1 (M0) and (2) organotypic spinal cord from rat foetuses. We also studied neuroinflammation in 2D with primary microglia cells stimulated with lipopolysaccharide (LPS). Samples treated with good manufacturing practices (GMP)‐grade EVs were assessed, combining functional analyses, protein and gene expression. In the functional muscle model, EVs protect the cells from death after damage, decreasing cCAS3 and stimulating cell proliferation. The protein array and gene results highlighted that EVs act through the downregulation of the TNFα factor. In parallel, in both neuroinflammation‐induced microglia and organotypic spinal cord‐damaged models, EVs regulated the neuroinflammation by inhibiting TNFα and promoting neural axon sprouting. In summary, EVs guard great potential for tissue regeneration by TNFα modulation, promoting muscle‐neural regeneration.

Workflow of the work. (1) Human muscle biopsies were collected, and the human muscle precursor cells (hMPC) were isolated, followed by co‐culture with human monocytes (THP‐1). In parallel, human muscles were decellularised to obtain an extracellular matrix (ECM) free of cells. ECM were recellularised by injecting hMPC and THP1 into the matrix. The recellularised ECM was induced to skeletal muscle loss by damaging the sample with cardiotoxin (CTX). (2) Good Manufacturing Practice (GMP) grade mesenchymal stromal cells were expanded and the GMP‐grade extracellular vesicles (EVs) were isolated. (3) Recellularised damaged ECM was treated with EVs, and a reduction/downregulation of TNFα was observed. (4) Spinal cord was isolated from a rat foetus to create an organotypic spinal cord culture to analyse the axonal psprouting. (5) EVs were used to treat organotypic spinal cord culture supported sprouting of the neural projections and induced a reduction /downregulation of TNFα expression was observed (Image created using Biorender.com).

## Linked entities

- **Proteins:** TNF (tumor necrosis factor)
- **Species:** Homo sapiens (taxon 9606), Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, ARG1 (arginase 1) [NCBI Gene 383], MIR206 (microRNA 206) [NCBI Gene 406989] {aka MIRN206, miRNA206, mir-206}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, MYH14 (myosin heavy chain 14) [NCBI Gene 79784] {aka DFNA4, DFNA4A, FP17425, MHC16, MYH17, NMHC II-C}, MIR215 (microRNA 215) [NCBI Gene 406997] {aka MIRN215, miRNA215, mir-215}, MIR21 (microRNA 21) [NCBI Gene 406991] {aka MIRN21, hsa-mir-21, miR-21, miRNA21}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, Gdnf (glial cell derived neurotrophic factor) [NCBI Gene 25453] {aka gndf}, NOTCH1 (notch receptor 1) [NCBI Gene 4851] {aka AOS5, AOVD1, TAN1, hN1}, MIR3196 (microRNA 3196) [NCBI Gene 100423014] {aka mir-3196}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, TNFRSF8 (TNF receptor superfamily member 8) [NCBI Gene 943] {aka CD30, D1S166E, Ki-1}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, MYOD1 (myogenic differentiation 1) [NCBI Gene 4654] {aka CMYO17, CMYP17, MYF3, MYOD, MYODRIF, PUM}, TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076] {aka CLGI, EPA, EPO, HCI, TIMP, TIMP-1}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Tnf (tumor necrosis factor) [NCBI Gene 24835] {aka RATTNF, TNF-alpha, Tnfa}, CD63 (CD63 molecule) [NCBI Gene 967] {aka AD1, HOP-26, ME491, MLA1, OMA81H, Pltgp40}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Cntf (ciliary neurotrophic factor) [NCBI Gene 25707], Icam1 (intercellular adhesion molecule 1) [NCBI Gene 25464] {aka CD54, ICAM, RICAM-I}, CD9 (CD9 molecule) [NCBI Gene 928] {aka BTCC-1, DRAP-27, MIC3, MRP-1, TSPAN-29, TSPAN29}, ALB (albumin) [NCBI Gene 280717], Timp1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 116510] {aka TIMP-1, Timp}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, Mtpn (myotrophin) [NCBI Gene 79215] {aka Gcdp}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, MYOG (myogenin) [NCBI Gene 4656] {aka MYF4, bHLHc3, myf-4}, CD81 (CD81 molecule) [NCBI Gene 975] {aka CVID6, S5.7, TAPA1, TSPAN28}, TRAF2 (TNF receptor associated factor 2) [NCBI Gene 7186] {aka MGC:45012, RNF117, TRAP, TRAP3}, ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}
- **Diseases:** muscle degeneration (MESH:D009410), Muscle defects (MESH:D009135), skeletal muscle loss (MESH:D005207), tissue injury (MESH:D017695), fibrosis (MESH:D005355), Muscle Damage (MESH:D009133), Inflammation (MESH:D007249), congenital malformation (OMIM:163000), muscle (MESH:D019042), tumour (MESH:D009369), Neuroinflammation (MESH:D000090862)
- **Chemicals:** L-Glutamine (MESH:D005973), CO2 (MESH:D002245), EGTA (MESH:D004533), water (MESH:D014867), Calcein (MESH:C007740), ribonucleosides (MESH:D012263), SPD304 (MESH:C527814), TRIzol (MESH:C411644), sucrose (MESH:D013395), lipid (MESH:D008055), PFA (MESH:C003043), LPS (MESH:D008070), deoxyribonucleosides (MESH:D003853), Glu (MESH:D018698), SDS (MESH:D012967), ascorbic acid (MESH:D001205), Gentamicin (MESH:D005839), Tween 20 (MESH:D011136), CaCl2 (MESH:D002122), Fluo-4 (MESH:C409648), KCl (MESH:D011189), Pen (MESH:C058388), hyaluronic acid (MESH:D006820), Alcian Blue (MESH:D000423), calcium (MESH:D002118), Q-VD-OPh (MESH:C468548), DAPI (MESH:C007293), glucose (MESH:D005947), GlutaMAX (MESH:C054122), betadine (MESH:D011206), prednisolone (MESH:D011239), Sodium deoxycholate (MESH:D003840), NaCl (MESH:D012965), aluminium (MESH:D000535), pyruvate (MESH:D019289), NaHCO3 (MESH:D017693), MgCl2 (MESH:D015636), Hoechst (-), OCT (MESH:C051883), oSpC (MESH:C067973), phalloidin (MESH:D010590), steel (MESH:D013232), Penicillin (MESH:D010406), Pluronic F-127 (MESH:D020442), sulfinpyrazone (MESH:D013442), GAG (MESH:D006025), nitrogen (MESH:D009584), PMA (MESH:D013755), Latrunculin B (MESH:C037068), EDTA (MESH:D004492), Amphotericin (MESH:D000666), Lipofectamine (MESH:C086724), dexamethasone (MESH:D003907), Streptomycin (MESH:D013307), 2-Mercaptoethanol (MESH:D008623), Triton X-100 (MESH:D017830), LAM (MESH:C050016)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** N  2682P
- **Cell lines:** BALB/C — Mus musculus (Mouse), Transformed cell line (CVCL_4350), BV-2 — Mus musculus (Mouse), Transformed cell line (CVCL_0182), SpC — Siniperca chuatsi (Mandarin fish), Spontaneously immortalized cell line (CVCL_C0WY), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), hMPC — Mus musculus (Mouse), Factor-dependent cell line (CVCL_RB19)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12978157/full.md

---
Source: https://tomesphere.com/paper/PMC12978157